Menu
Primary Navigation
–
Pages, Posts & Categories
Home
Posts
The role of Indigenous knowledges in psychedelic science
23. January 2022
Ayahuasca & CogPsy
23. January 2022
Psilocybe induced rejuvenation (Reddit)
14. January 2022
Gilgamesh and the Magic Plant
30. December 2021
Ueber Pellote – Ein Beitrag zur pharmakologischen Kenntniss der Cacteen
29. December 2021
Psilocybin study enrolls clinicians with COVID-linked blues
29. December 2021
Predicting Reactions to Psychedelic Drugs: A Systematic Review of States and Traits Related to Acute Drug Effects
26. December 2021
The subjective experience of acute, experimentally-induced Salvia divinorum inebriation
26. December 2021
Identification of a novel member of the family Betaflexiviridae from the hallucinogenic plant Salvia divinorum
26. December 2021
Salvia divinorum: from recreational hallucinogenic use to analgesic and anti-inflammatory action
26. December 2021
Chemical syntheses of the salvinorin chemotype of KOR agonist
26. December 2021
Salvia divinorum increases alcohol intake and tonic immobility whilst decreasing food intake in Wistar rats
26. December 2021
Sociological investigations of human enhancement drugs: The case of microdosing psychedelics
26. December 2021
Tactics of Legitimation in the Psychedelic Sciences: Lessons for Feminist Sociology of Knowledge
26. December 2021
The Effects of Tryptamine Psychedelics in the Brain: A meta-Analysis of Functional and Review of Molecular Imaging Studies
25. December 2021
Schopenhauer on death (Thanatology)
25. December 2021
Arthur Schopenhauer and psychiatry 200 years after the publication of The World as Will and Representation
24. December 2021
A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses
22. December 2021
The Therapeutic Potential of Psilocybin
22. December 2021
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
21. December 2021
5-Methoxy- and 5-Hydroxyindoles in the skin of Bufo alvarius
19. December 2021
Ayahuasca-Tourismus in Peru: Motivationen und subjektive Bedeutungen bei Teilnehmern von Ayahuasca-Retreats im oberen Amazonasgebiet
19. December 2021
The personal experiences of ayahuasca brew users as a therapeutic catalyst for substance dependence: A qualitative exploratory approach
19. December 2021
Exploring the effect of Trichocereus pachanoi on the depression-like behavior in rats
17. December 2021
Mescalina y ritual del cactus de san Pedro: evidencias arqueológicas y etnográficas en el norte de Perú
17. December 2021
Use of Benefit Enhancement Strategies among 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) Users: Associations with Mystical, Challenging, and Enduring Effects
15. December 2021
Intensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study
15. December 2021
DMT Models the Near-Death Experience
15. December 2021
Neural correlates of the DMT experience assessed with multivariate EEG
15. December 2021
Fractal in HTML & CSS
15. December 2021
Bioactive Components of Salvia and Their Potential Antidiabetic Properties: A Review
15. December 2021
Dark Classics in Chemical Neuroscience: N, N-Dimethyltryptamine (DMT)
14. December 2021
Harnessing psilocybin: Antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice
14. December 2021
Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment
14. December 2021
Tabernanthalog—a water-soluble, non-hallucinogenic, non-toxic analogue of ibogaine
11. December 2021
Newtonian fractal
11. December 2021
A systematic review of psychedelic-assisted psychotherapy for mental health: An evaluation of the current wave of research and suggestions for the future
10. December 2021
Neural Mechanisms and Psychology of Psychedelic Ego Dissolution (Peprint)
10. December 2021
Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention
10. December 2021
The Evolved Psychology of Psychedelic Set and Setting: Inferences Regarding the Roles of Shamanism and Entheogenic Ecopsychology
10. December 2021
Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey
10. December 2021
Recreational use of psychedelics is associated with elevated personality trait openness: Exploration of associations with brain serotonin markers
10. December 2021
5-Hydroxytryptamine and Intestinal Flora on Depressive-Like Behavior Induced by Lead Exposure in Rats
6. December 2021
Serotonin, fearfulness, dominance, and trainability in horses
6. December 2021
Serotonin and cancer
6. December 2021
Serotonin, dopamin and orgasm
6. December 2021
The use of Psilocybin in oncology
3. December 2021
Psilocybin for the treatment of bipolar depression: A review
3. December 2021
Psychedelic (R)Evolution
3. December 2021
Psilocybin induces dendritic spine formation
3. December 2021
Psilocybin & Genetic Ageing
28. November 2021
Slide
Pages
Psychedelics & Shadow-work
Home
Contact
Psychedelic Webdesign
Bitcoin TradingView Widget
Etymology of the term psychedelic
Post with image
Psychedelic companies
JCU
Sir Arthur Eddingtons parabel of the ichthyologist
Psychedelic web-projects
Sir Arthur Eddington: The Philosophy of Physical Science (1938)
Clinical Trails
References 2021
The world is a psychedelic lab (animation)
Clinical trials with psychedelics in 2021
Psilocybin patents
Psilocybin & depression
5-methoxy-N,N-dimethyltryptamine: An ego-dissolving neurochemical catalyst of creativity
Credits
Dataprotection & Legal Disclaimer
Lectures & Presentations
WikiGalaxy
Interactive generative art
Cosmic symbolism
References for psychedelic therapy network
Test DHTML sidebar
Animated Psychedelic-Lab SVG logo
Post overview (list format)
Psychedelics & Fractals
Sitemap
Psychedelic stock watchlist
Psychonautic & Cybernetic
DMT case report (Strassman, 2001)
DMT patents
Psilocybin patent fillings
MDMA patents
Psychedelic Unselfing and Moral Perception (Master thesis)
Psychedelic Collage
Contact form
Meditation – Yoga Nidra
Random Quotes
Neuromodulatory effects of psychedelics: An interactive visual synopsis
Mindmap – Transdisciplinary psychedelic science
Psychedelics and awareness
Psyche & Chronos: Psychedelics and phenomenological time perception
☸️ Mandukya Upanishad
Psychedelics & Cybernetics
Intelligent design
Substances used in project Bluebird, Artichoke, MK-Ultra, and MK-Delta
Putnams “Brain in a vat” (solipsism, naive realism, skepticism and content externalism)
The search for the manchurian candidate
Inner and outer dimensions
Transcending academic and epistemic boundaries: Psychoactive tryptamines and the frontiers of human exploration
Slide
Categories
5-MeO-DMT
Ayahuasca
DMT
Iboga
Media
Mescaline
Psilocybin/Psilocin
Psychdelic Webdesign
Salvia
Varia
Slide
Current location
–
Breadcrumb trail
Path:
Home
/
Clinical trials with psychedelics in 2021
RSS News Feed
–
Dynamically generated updates
Slide
Israel Isn’t a Leader in Psychedelic Healing - It’s an Apartheid State
How I Ease my OCD and Anxiety with Psychedelics
8 Songs for Transformational Psychedelic Mushroom Experiences
How Psychedelic Mushrooms Support Me
Disclosure: IUSA5: A Randomized, Delayed Treatment Control Phase 2 Study of the Safety and Effectiveness of Manualized MDMA-Assisted Therapy for the Treatment of Social Anxiety Disorder
Statement on Clinical Treatment Practice using Cannabis to Treat Patients with Symptoms of Posttraumatic Stress Disorder (PTSD)
Zendo Project Prepares Provide Peer Support at Burning Man 2022
June 2022 Giving Report: Donors Give Over $373,000 to Psychedelic Research and Education
MDMA Therapy Training Program Update: July 2022
Statement: Biden Administration Preparing for Potential FDA Approval of MDMA-Assisted Therapy for PTSD
MDMA and Healing a Dis-regulated Nervous System
First Participant Completes Treatment in Phase 2 Study at the Bronx, New York Veterans Affairs Medical Center
First Participant Screened in Open-Label, Phase 2, Multicenter Feasibility Study of Manualized MDMA-Assisted Therapy with an Optional fMRI Sub-Study Assessing Changes in Brain Activity in Subjects with PTSD in Europe
MAPS Launches Psychedelic Fundamentals, an Online Education Curriculum From Leading Psychedelic Organization
GH Research Reports First Quarter 2022 Financial Results and Provides Business Updates
GH Research Reports Full Year 2021 Financial Results and Provides Business Updates
GH Research Reports Third Quarter 2021 Financial Results and Provides Business Updates
GH Research Announces Successful Outcome of the Phase 2 part of its Phase 1/2 Clinical Trial of GH001 in Treatment-Resistant Depression
GH Research PLC Provides Business Updates and Reports Second Quarter 2021 Financial Results
GH Research PLC Announces Pricing of Initial Public Offering
GH Research Announces Closing of $125 Million Oversubscribed Series B Financing
GH Research Ltd. Announces Completion of Phase 1 Clinical Study with GH001 (5-Methoxy-N,N-Dimethyltryptamine) in Healthy Volunteers and Updates on Further Progress
Slide
Israel Isn’t a Leader in Psychedelic Healing - It’s an Apartheid State
Israel Isn’t a Leader in Psychedelic Healing - It’s an Apartheid State
Publication date: 05-15-2020
Open full article in lightbox
Art by Nikolitsa Paranomos. Image description: Psychedelic blue and white background over the apartheid wall with Palestinian resistance art that reads, “to exist is to resist.” By Amanda GelenderIsrael has recently been featured , heralded as a leader for its investment in psychedelic clinical trials for MDMA-assisted psychotherapy for Post-Traumatic Stress Disorder (PTSD). Israel is the first national government to approve MDMA as part of a “Compassionate Use” program, which allows people to use clinically unproven treatments because their suffering is so severe and unresponsive to available medical interventions. The clinical trials enlist Israelis suffering from PTSD, including Israeli soldiers who have served in the Israeli Defense Forces (IDF). Phase 2 clinical trials for MDMA as a safe and effective treatment for PTSD. Yet when we lean too heavily on the medical model to address mental health challenges, we often miss the root causes of a system of suffering. In this case, the PTSD is not individual pathology or sickness, rather it stems from the ongoingof Palestine.Psychedelics are not and never will be politically neutral: They are rooted in, inextricably tied to and . The use of psychedelics either support or upend the status quo, and the integrity of the psychedelic movement relies on human rights and to always be at the forefront of our work. I agree that everyone deserves healing: PTSD is painful, no matter who experiences it or what the cause is. 18-year old Israelis must serve in the military - they are forced to carry out state violence and clearly the mental health toll is devastatingly high. But
psychedelic healing must first and foremost be a tool to support the freedom of the oppressed - not a balm to soothe those who carry out oppression.
In a , a representative of the Charles and Lynn Schusterman Family Foundation, one of the partners of the MDMA clinical trials, stated: “A society is only as strong as how it cares for its most vulnerable communities. I am proud that Israel is leading the world in exploring new ways to support and treat people suffering from PTSD and psychiatric illnesses. The Compassionate Use program in Israel is an opportunity to
help high-risk populations
[emphasis mine], including IDF soldiers who have served their country, whose mental health needs are often overlooked and underserved [...] over 10% of the Israeli population experiences PTSD, and this figure increases significantly in regions frequented by rocket attacks. Military service is compulsory, and most families in Israel have histories of trauma and persecution.”The “vulnerable community” and “high-risk population” whose “” with “” that is mysteriously absent from the press release, however, are Palestinians. Today is the 72nd anniversary of (meaning “the catastrophe” in Arabic) commemorating the period of time when were dispossessed from their homes to form the state of Israel, more than 450 villages burned. Now in 2020, Palestinians still fight daily for the rights guaranteed to them .Major human rights organizations on the plight of the Palestinians: Israel subjects Palestinians to ongoing persecution that strips their right to personhood, freedom, health, and liberty. Gaza is the site of a and has been called the because in and out of the region, controlling and limiting the supply of , , , and . Israel severely restricts Palestinians’ and subjects them to ,, , , , , and . The has grown to millions of Palestinians - entire generations of families displaced from their homes. Israel enforces , with two very different systems for Jewish and non-Jewish people. I’ll note here that I’m a Jewish American who, like many of my peers, was raised to believe that Israel was a benevolent underdog.If those of us invested in the work of psychedelics ignore the political realities around psychedelic healing, we can become an accomplice to human rights abuses, helping the violent status quo to strengthen and persist. This is another way that the medical model fails us: As long as systems of oppression are firmly in place, there is an endless stream of “patients” seeking medicine to manage something that is much bigger than any one individual. As Jiddu Krishnamurti said, “It's no measure of health to be well adjusted to a profoundly sick society.”It’s also important to follow the money. Israel is deeply invested in becoming an entrepreneurial center of gravity with a booming that includes and businesses. Psychedelic investment by the state of Israel is inextricably tied to its economic interests: An emerging wave of psychedelic and see a tremendous (a for another day) and of course Israel wants to be on the cutting edge. Note that Israel is also of U.S. foreign assistance since World War II, currently receiving about $3.8 billion every year () specifically in military funding. In this way, Israel profits from instigating military violence and it profits from healing the trauma of violence.
They manufacture the illness and the cure.
It’s a compelling open question under what conditions could psychedelics help shift the minds and hearts of people who hoard resources, commit violence, or otherwise uphold oppression. But any project of that nature must be led by those most impacted by injustice, with a political framework that accurately portrays the political reality and power imbalance at play. And it must be accompanied by the understanding that the ultimate goal is to change the systemic conditions that cause suffering, not just to personally feel at peace amidst injustice.This comes at a time when Palestinians call on the world to support their fight to hold Israel accountable to international human rights law. This is the movement and it encompasses everything from to from companies that profit from the Israeli occupation. BDS is a form of non-violent protest notably fighting for freedom from apartheid. There is also a growing movement of allied who speak out and who refuse to serve as soldiers and execute the occupation. When individuals carry out oppression, everyone involved loses their humanity. I say this as a Jewish person who has seen Israel uphold the occupation in my name. It’s devastating to have your community face unspeakable, genocidal suffering only to turn around and become the violent oppressor. And as an American, I know that taxpayer money funds these catastrophic human rights violations. There aren’t enough psychedelics in the world to wash the blood off of our hands.It would be powerful to see commitments from people across the psychedelic field that support the Palestinian people in their struggle for justice. It is vital that psychedelic research teams , , and expand their scope beyond the medical model to really capture the full magnitude of potential psychedelic impact on the global majority. We must always keep our eye on the systemic conditions that cause human suffering because
psychedelics are not meant to heal us back into oppressive systems.
We must apply our psychedelic journeys to birth better worlds. As psychedelics often teach us, our fates are intertwined: Palestinian liberation makes us all more free.
A huge thank you to my creative collaborators Alex Bledsoe and Nikolitsa Paranomos for your support with this piece.
How I Ease my OCD and Anxiety with Psychedelics
How I Ease my OCD and Anxiety with Psychedelics
Publication date: 03-10-2020
Open full article in lightbox
Art by . Image description: Shadow of a person from behind standing on a grass and flower lined path with gold steps in a sea of blue glass overlooking purple mountains and a sunrise. By Amanda GelenderI have struggled with OCD and anxiety for about 25 years. My OCD has shapeshifted over time, camouflaging into each phase of my life, but the themes have remained pretty consistent through the years. At this point in my life, my OCD could perhaps best be described as meaning that while I have compulsions, obsessive and intrusive thought loops are the most debilitating aspects of my condition. At times, OCD fear loops have been so overwhelming that entire parts of my life shut down - for example, I stopped driving for years because I couldn’t shake the terrifying fear that I would accidentally hurt someone.I have been fortunate enough to work with many different healing modalities throughout my life, including talk therapy, community support networks, acupuncture, medications (), cannabis, peer-support group therapy, physical movement, nature, and creative practices. I have also worked extensively with psychedelics to manage my OCD, anxiety, and depression. While I don’t seek or expect a “cure” to my mental health challenges, LSD and psychedelic mushrooms are life changing tools to work through my fears and come to peace with myself, facilitating some of the most transformational healing work of my life.Working with psychedelics to support folks with OCD and anxiety is a topic of deep interest to me both personally and professionally: In addition to my own experiences, my work is to facilitate with psilocybin mushroom truffles. I’m not a doctor or therapist, I facilitate experiences as someone with extensive experience with psychedelics and a love for creating the conditions for others to benefit from them the way I have. Many of the people who reach out for sessions experience anxiety and/or OCD, so I’m frequently in conversation with folks about whether psychedelics may be helpful tools to support them. There are still many open questions about how and why psychedelics impact people the way they do - this is not merely a scientific inquiry, it is also political, philosophical, cultural, and spiritual. In this age of crumbling drug prohibition, western science is trying to catch up to what about the healing potential of entheogenic plant medicine. Researchers have only begun to scratch the surface on psychedelic applications for and , but so far are very promising. I’m confident that in the coming years, psychedelic medicine will become mainstream treatment for a broad range of mental and physical health challenges. We just have to keep our focus on access and , being wary of how these incredibly powerful tools may be and a for-profit medical system.In a neurological context, about classic psychedelics and the brain is that it temporarily quiets down the “default mode network,” a part of the brain that filters and communicates information between various regions. So when the default mode network goes off duty during a psychedelic trip, parts of the brain can communicate that don’t usually talk to each other and new neural connections . We suddenly have unfiltered access to a slew of information, memories, and feelings that are often difficult to tap into in our standard state of consciousness. It can help us feel what some call “ego dissolution,” a sensation that changes , which to the positive benefits of psychedelics. Below is of brain scans depicting the neural connections with psilocybin (image b) and a placebo (image a): Brain scans showing connectivity with psilocybin (right) and with a placebo (left). Credit: Petri et al./Proceedings of the Royal Society Interface But what does this mean on a practical level? Well, it’s different for everyone. I have found that in the psychedelic state it’s easier to go past the mind and work through trauma in my body. I can release control and explore my deepest fears and traumas at the root of my anxieties. I can hold myself with compassion and feel through repressed emotions, tapping into a sense of universal oneness and spiritual connection. I can feel tremendous joy, sorrow, rage, euphoria, and humility, a powerful emotional catharsis that cleans my pipes. In the time after a trip, there is often a window of that can particularly support folks with depression and anxiety - it often feels a bit easier to try new things and shake up old habits. I feel more present and aware of what I want. I feel re-energized, appreciative, and grounded. Ideas, fresh perspectives, and creativity comes more easily. My connections and community work deepens. All of these shifts help ease the daily struggle of anxiety.Of course when we ask a question like, “How can psychedelics help relieve anxiety?” we have to remember the context in which we attempt to heal: Racialized capitalism. We live under political systems that exacerbate and facilitate trauma and perpetual anxiety, particularly for Black and Brown people. It’s very hard to heal yourself in an environment that continues to inflict harm. So we have to remember that while mental health challenges can feel like individual plights, they are often not so much personal pathologies as they are natural ways of responding to our environment. While psychedelics are incredibly powerful tools for exploration and healing, to truly address the roots of mental health crises, our focus must always be on systemic level change.From what I have witnessed with clients, people heal differently with these tools and it can change over time. Some folks have a radical shift after a trip, others may have a more subtle shift or may not resonate with this modality at this point in their life. A trip that facilitates a strong sense of interconnectedness with the universe (ego “death” or dissolution) who struggle with depression and anxiety. But in my experience, ego dissolution isn’t a prerequisite for substantial healing with psychedelics. I like to remind clients that the wisdom from psychedelic sessions can come in many forms: Just because there may not be a stark, immediate shift after a trip doesn’t mean that important work isn’t being done. Rather than a silver bullet, I view psychedelic sessions as powerful steps on a healing and growth path. Each trip I shed another layer and go deeper - it’s a process that can take time. So while my work with psychedelics hasn’t eradicated my OCD or anxiety symptoms, the volume has turned down, and I have renewed mental, emotional, and spiritual fortitude to traverse challenges when they arise. A great example is my writing - OCD would want to block me from publishing this piece (“Have I checked it enough times to see if I said something incorrect? Will I accidentally cause damage with what I share?”...) but I move through the fear and publish anyway. It’s not that those voices aren’t there, it’s that they don’t drive and control my life the way they used to. In working with psychedelics through the years, I’ve become less fear-based. I feel more aligned and at peace with the natural ebb and flow of things.I have also found that psychedelics work well in partnership with other healing modalities. People who have healing practices in place before their trip often have an easier time integrating the lessons from psychedelic journeys. By the same token, psychedelics can enhance existing practices, helping people go deeper and unlock new levels in talk therapy, meditation, and artistic expression, for instance.
Trip Tips for Folks with OCD & Anxiety
The many unknowns of a psychedelic journey can be the perfect catalyst for worry, particularly for those of us with a proclivity towards looping, catastrophizing, and worst-case scenarios. It’s completely normal to be scared before a psychedelic journey - I was certainly terrified before my first psychedelic trip and I’m so grateful to have had thorough preparation and a supportive person there with me to help me feel safe in my exploration.A wide range of experiences are possible in a psychedelic journey and even healing trips can sometimes feel scary or even traumatic. In my experience, going through these dark places in psychedelic journeying can still bring great positivity, but only if the container around the trip is supportive. This is which found that the majority of people who have had challenging psychedelic mushroom experiences still said they were “‘meaningful’ or ‘worthwhile,’ with half of these positive responses claiming it as one of the ” To set yourself up for a safe and transformational session, it’s always wise to follow basic prep guidelines - access the medicine from a trusted and safe source (testing the substance if necessary), know a good starting dose, may affect your trip, prepare and feel as centered as possible before the journey (set), arrange for a safe and nourishing space (setting), have a person with you for support (sitter or guide), and allot time to process in the days following the session (integration). I actually think that a healthy mix of nervousness and excitement before a trip is a good thing: It demonstrates that you have reverence for how powerful a psychedelic teacher is and that it has the potential to significantly shift your life. But of course it’s best not to go into a trip feeling too anxious, so practice grounding yourself before the journey. And if you’re really struggling the days leading up to the trip - don’t push it. Check in with yourself and see if you want to postpone your trip or start with a lower dose. It’s also important to note that psychedelics aren’t for everyone and it can shift depending on what you’re going through. For instance, I don’t go on full dose trips when I am in a depressive crisis, a particularly bad OCD episode, or when I’m very stressed or overworked. I’ve found that these trips can be unnecessarily challenging or even temporarily damaging, so I wait until I feel a bit more stable to have a session. After your trip, be kind to yourself and take time to process in whatever ways feel most natural to you. It can be particularly helpful to write, draw, rest, and be in nature in the days following your journey. It’s normal to feel many things after a trip so let the changes unfold over time and don’t rush to make sense of everything. Be patient if changes don’t come right away and remember that for those of us who struggle with anxiety and OCD, just the act of releasing control and taking the leap into the psychedelic journey is a huge achievement.
8 Songs for Transformational Psychedelic Mushroom Experiences
8 Songs for Transformational Psychedelic Mushroom Experiences
Publication date: 02-27-2020
Open full article in lightbox
Digital drawing of purple, yellow and pink smoke flowing through broad green leaves. Art by Nikolitsa Paranomos.
By
While the impact of music on psychedelic sessions is currently an ongoing , music has been a powerful component of psychedelic journeying for centuries, rooted in indigenous, ceremonial practice with plant medicine. In the context of psychedelic mushroom journeying outside of a shamanistic practice, musical considerations are personal as well as cultural. Not everyone responds well to the most common types of music played in retreat and clinical settings - for instance, clients grappling with the impact of white supremacy on their psyches may be less likely to resonate with classical music that harkens back to colonization. “World” music selected without proper cultural context can miss the mark and feel exoticizing. We need more research focused on experiences of people of color from a wide range of backgrounds to really understand how music can foster breakthroughs in psychedelic sessions.At our in Amsterdam, we support people from many walks of life through legal, sliding-scale, private psychedelic mushroom experiences. Time and again, we’ve witnessed how the right songs played at the right time can facilitate tremendous breakthroughs in psychedelic sessions. We have an individualized approach to music selection: Rather than follow a set playlist, we live-DJ for our clients, pulling from our extensive catalogue of songs to support moment-to-moment flow. We also ask clients to send us music that holds particular significance for them: Peppering in these personal tracks during key moments creates an opportunity to process through emotions, memories, traumas, and relationships.Our individualized approach also means that as guides we are exposed to a steady stream of fresh musical tracks from our clients from around the world. I’ve pulled eight pieces of music from our library that we love to play during client sessions - enjoy! The Come Up
&
- -
The hypnotic, loving music of Beautiful Chorus is a staple for our sessions. Faith’s Hymn and the chakra tracks from their Resonance Meditation album create a soothing, womb-like atmosphere. These songs facilitate a warm, other-worldly invitation into the psychedelic journey. We often play these songs on loop in both the come up and the come down of a session. (Shout out to our collaborator Alex Bledsoe who put us on to their stunning music!)
- -
Radiohead guitarist Jonny Greenwood received an Oscar nomination for his original score for the 2017 film Phantom Thread and this particular track from the film is a go-to for when the trip begins to lift off. The rolling crescendos usher in a fresh, enchanting state of being to set the stage for the journey. The Peak
- -
We love to play this track during the transition from the come-up into the peak of the experience. It’s almost completely instrumental except for the mantra “let it go” spoken as the beat picks up. This song’s layered, hypnotic vibe combined with a powerful mantra of release supports breakthroughs at a time in a trip when surrendering is key.
- -
We were first introduced to Kamasi Washington by a jazz writer client who sent along some of his music for her session. We loved the tracks so much that we incorporated his work into our library. Integrity is hypnotic and layered, definitely worth repeating.
- -
This is a classic track by the legendary Nigerian Afrobeat artist Fela Kuti. It’s an intense, sweeping selection to experience on a psychedelic trip so we save it for the fervency of the peak. We’ve found this song to be a particularly strong choice for Black and Brown clients doing ancestral and work during their session.
- -
This beautiful 2016 track is gentle but rhythmic, invoking the feeling of riding a wave or moving through water. It can play on loop and doesn’t overwhelm the senses, guiding you through a psychedelic state with inspiration and ease. It’s also a wonderful track to create art with on a psychedelic journey. The Come Down
- -
This is one of our favorite songs to loop during the comedown of a psychedelic trip. KOKOROKO is a truly genius Afrobeat collective out of London whose music is at the same time calming and stirring. As clients float back to this plane from their session, the vibes of Abusey Junction are often a welcome homecoming.
-
As the revelations and breakthroughs of a trip are setting in after a full journey, this song brings a loving and poignant presence. It’s a great choice for when folks are coming more fully back into their bodies and can manage a track with lyrics. Nina Simone’s version of this song is a particularly compelling and beautiful choice, given her legacy as a and musical force of nature.We’re always creating new lists and would love to send them directly to you - to catch the vibe.
How Psychedelic Mushrooms Support Me
How Psychedelic Mushrooms Support Me
Publication date: 02-20-2020
Open full article in lightbox
Digital drawing of a blue mushroom with gold strands, circled by pastel painted green leaves. Artist:
By
This piece is my contribution to the #ThankYouPlantMedicine campaign to de-stigmatize and psychedelic plant medicine. From microdosing to full dose experiences, psilocybin “magic” mushrooms have supported me tremendously me over the years. I also work intentionally with cannabis, which continues to bring me healing and positive transformation. For context, I have struggled for many years with several mental health challenges including OCD, depression, and anxiety. I’ve been on prescription medications over the years and am currently on an SSRI . I’m from the Bay Area and live in the Netherlands where psilocybin is legal for purchase in the form of mushroom truffles. I’m the founder of a sliding-scale in Amsterdam - my team and I support people from around the world through psychedelic mushroom truffle sessions with the goal of helping to create a more just, equitable, and sustainable world. Through my own personal transformations and the many client sessions I’ve facilitated, I’ve seen first-hand how with supportive preparation (set) and environment (setting), psychedelic mushrooms have tremendous potential to support people in a multitude of ways (something that indigenous people have ). Learning to work with psychedelics has been an ongoing process: Along with euphoric and joyful moments in trips, I’ve also had very challenging experiences where I was grateful to have a nourishing environment and supportive person at my side. While psychedelics are not for everyone at all points in their lives, they are now a vital part of my wellness and social change work. They also complement and enhance the therapeutic benefits of my other healing modalities. I believe that psychedelic plant medicine, including psilocybin and cannabis, should be and widely accessible for people to grow and share in community. Our focus must always prioritize , , and over - a significant battle under racialized capitalism. But any movement to reduce individual pain has a responsibility to address the systemic causes of suffering. The rise of psychedelic medicine must include to address the generations of damage inflicted on Black and Brown communities through , , and the . The global struggle for indigenous rights is and to all plant medicine practice. I write my story about working with mushrooms in part because my whiteness shields me from impunity - I can speak openly about substance use with less risk than my friends of color. My ability to work with largely illegal medicines as openly as I do and with as little friction as I experience is a direct result of my whiteness - all of the times I have
not
been by police, for instance. I hope our collective stories shared today lead to positive, systemic change. Here are ways psilocybin mushrooms have supported me:
New Ways of Perceiving
In mushroom sessions, I can access fresh perspectives on all facets of life. It can sometimes feel like being given a universal key to explore every room in the house of . I can wander into any space and explore memories, desires, and fears in ways that often feel inaccessible in my standard state of consciousness. Heightened sensations and perceptive shifts in psychedelic sessions allow me to continually gain a deeper understanding of myself and the world around me. This is particularly helpful as someone who frequently experiences anxiety and depressive loops: A new mindset and path forward can mean . Everything I encounter during a psychedelic journey can teach me a lesson, a mindset that also serves me well in daily life. I marvel with profound curiosity and appreciation for everything around me, even if I don’t have language to describe its complexity.
Creative Flow
Mushrooms help me to create without self-censoring. I write and draw freely and unselfconsciously, focused on the joy and power of creating rather than the output. New ideas emerge organically. I deepen my appreciation for music, art, poetry, and natural beauty, as I can perceive these mediums with enhanced meaning and feeling. I gain more forgiveness and understanding for my own creative process, helping me release the shame of not producing “enough” or “better.”
Feel my feelings
Mushrooms help me to feel my feelings with depth and profundity - I often weep, rage, marvel, and burst into uncontrollable laughter. Accessing the entire emotional spectrum helps me to better understand and appreciate my multitudes. The catharsis of full, embodied emotional release on psychedelics has been tremendously healing. Psychedelics help me process through trauma not just cognitively but with my whole being (body, mind, spirit).Psychedelics let me access a well of inner wisdom which gives me a sense of safety, security, and groundedness in my daily life. In working with mushrooms and cannabis over the years, I now feel less resistance to change and more at ease in transition. Even though I have a long way to go in releasing my perfectionism and unnecessary fears,
it’s been a relief to feel more at peace with the natural ebb and flow of things - endings, beginnings, birth, life, death.
Embodiment
Mushrooms help me feel through pain and and programmed into my cells. I can work through and more easily release body shame. I can explore my embodied experience of gender and sexuality. I often experience a resounding, indescribable sense of somatic gratitude which spills into my daily life, relationships, and social change work in the days and weeks to come.
Deepened Connections
After sessions, I often have an enhanced desire for deep connection. I feel more present with myself and others, grateful for the time we have together. I‘m open to new, aligned connections. Because my sessions help me tune into my wants and needs, I feel less fear in sharing my truth and asserting boundaries. After sessions I often initiate uncomfortable conversations that I had been putting off or take the leap to do something I’ve been wanting to do but felt too afraid. I often emerge from trips revitalized, nourished, in deeper connection with those around me, and with a spark of optimism, which feels particularly important and elusive in these bleak political times.
Fuel to Imagine and Build a Better World
We still have a lot to learn about how psychedelics impact and . But I certainly see their radical potential. Mushrooms can help us imagine possibilities outside of dominant paradigms and systems: Tunnels to a better world. Mushrooms let us dissolve boundaries and borders, reminding us that all of our fates are intertwined. They can help us engender deep empathy for all living things, reconnecting us with our roots in the natural world. Psychedelics are not just tools for individual improvement, as asserted by the medical model and dominant neoliberal paradigms. Our collective challenges are systemic and our solutions must be as well. Psychedelics aren’t a substitute for structural change, but they can open us up to new ideas, connect us to our values, and re-energize us to fight for structural solutions, breathing new life into our social change work.As adrienne maree brown, author of , , “Where we are born into privilege, we are charged with dismantling any myth of supremacy. Where we are born into struggle, we are charged with claiming our dignity, joy and liberation.” I think psychedelics can support all sides of this work. For those who experience oppression - particularly Black and Brown folks - psychedelics can be an access point to feel tremendous freedom and healing from generations of racial trauma. They can usher in powerful joy, release, and ancestral connection. They can with the process of , feeling freedom, worth, and truth outside of systems of oppression. And for those with privilege, we can work with psychedelics to explore how to best leverage our resources and positionality for a more just world. Mushrooms can help us all to dream up a better society and then boost our momentum and capacity to actually build that world.
Explore All Things - Mind, Consciousness, Dimensionality, Identity, and Spirituality
Mushrooms give us an opportunity tap into the interconnectedness of all things, the expansiveness of our consciousness, and the energy flow of the universe. They provide direct access to spiritual planes and ancestral wisdom (one the reasons why by indigenous sacred use of mushrooms was unmediated access to the divine). Each trip, mushrooms reveal more data in an unlimited stream of channels, windows, mirrors, and portals. They help to continually pull away at a seemingly endless series of veils, opening access into facets of dimensionality, nonlinear time, and consciousness. Psychedelic exploration will continue to have a tremendous impact on what we know about existence and consciousness.With mushrooms I can deeply explore facets of my queerness, race, sexuality, and gender. I can melt walls I’ve built to shield and protect myself from pain. I can muster the courage to walk into the basement of my subconscious and see what I’ve been too afraid to look at - trauma, guilt, shame, death, failure, abuse, resentment, anxiety, sadness, uncomfortable truths. This work can be painful and exhausting, but it can also be gentle and fortifying. Each session I gain more embodied strategies to accept all parts of myself and traverse life’s challenges. It has been some of the most profound healing work of my life.
Disclosure: IUSA5: A Randomized, Delayed Treatment Control Phase 2 Study of the Safety and Effectiveness of Manualized MDMA-Assisted Therapy for the Treatment of Social Anxiety Disorder
Disclosure: IUSA5: A Randomized, Delayed Treatment Control Phase 2 Study of the Safety and Effectiveness of Manualized MDMA-Assisted Therapy for the Treatment of Social Anxiety Disorder
Publication date: 08-02-2022
Open full article in lightbox
Social Anxiety MDMA-Assisted Therapy Investigation (SAMATI)
, of Portland Psychotherapy, is the sponsor and Principal Investigator for , an exploratory study to investigate the safety and preliminary efficacy of MDMA-assisted therapy for social anxiety in adults, and examine the physiological mechanisms through which it may be effective. The study is a randomized, open-label, delayed control study that aims to treat 20 participants diagnosed with moderate-to-severe social anxiety disorder (SAD) of the generalized subtype. SAD is the psychiatric disorder in the United States with widespread impact on individuals and society. SAD commonly leads to increased isolation, prevention of meaningful social relationships and employment, and contribution to comorbid psychiatric conditions such as Alcohol Use Disorder and Major Depressive Disorder. Despite its widespread impact, there is insufficient research into novel treatments for SAD. Improving the possible treatments for this condition has the potential for very high public health impact.Dr. Luoma’s clinical work and research focuses on factors that impede individuals’ sense of belonging and social functioning with a particular focus on shame, avoidance, and self-criticism, all of which are characteristics of SAD. Research suggests that MDMA-assisted therapy may target these feelings, therefore Dr. Luoma hypothesizes that MDMA-assisted therapy may demonstrate effectiveness in individuals with SAD. A previous MAPS-sponsored Phase 2 pilot study on the potential for showed promising results: Participants had statistically significant reductions in social anxiety as measured by the (LSAS) both one and five months after treatment. This trial aims to build on those results and further evaluate the potential of MDMA-assisted therapy for treating SAD within the general population. The study, for which (MAPS PBC) is providing MDMA, will be carried out by a team from the in collaboration with the . Portland Psychotherapy is self-funding this trial, relying on the organization’s and support from partners and donors. The researchers hope to pursue further studies in the future with larger sample sizes and access government funding. You can visit the study’s to find out more and if you wish to help.The post
Disclosure: IUSA5: A Randomized, Delayed Treatment Control Phase 2 Study of the Safety and Effectiveness of Manualized MDMA-Assisted Therapy for the Treatment of Social Anxiety Disorder
appeared first on
Multidisciplinary Association for Psychedelic Studies - MAPS
.
Statement on Clinical Treatment Practice using Cannabis to Treat Patients with Symptoms of Posttraumatic Stress Disorder (PTSD)
Statement on Clinical Treatment Practice using Cannabis to Treat Patients with Symptoms of Posttraumatic Stress Disorder (PTSD)
Publication date: 07-31-2022
Open full article in lightbox
On July 21, 2022, a general medical and psychiatric practice in Steinheim, Germany, about their use of cannabis to treat patients with symptoms of posttraumatic stress disorder (PTSD). The statement supports the idea of patient self-titration of how much subjects use each day, when they use, and route of administration, along with the amount of marijuana each subject will receive (2 grams per day) and the potency (about 20% THC).The post
Statement on Clinical Treatment Practice using Cannabis to Treat Patients with Symptoms of Posttraumatic Stress Disorder (PTSD)
appeared first on
Multidisciplinary Association for Psychedelic Studies - MAPS
.
Zendo Project Prepares Provide Peer Support at Burning Man 2022
Zendo Project Prepares Provide Peer Support at Burning Man 2022
Publication date: 07-27-2022
Open full article in lightbox
The Zendo Project is headed to Burning Man next month to provide psychedelic peer support, harm reduction, and education for the first time in three years! Our application is now closed, and we received an amazing 930 applications. Applications are currently still under review.We can’t wait to be in the dust with all our amazing volunteers!The post
Zendo Project Prepares Provide Peer Support at Burning Man 2022
appeared first on
Multidisciplinary Association for Psychedelic Studies - MAPS
.
June 2022 Giving Report: Donors Give Over $373,000 to Psychedelic Research and Education
June 2022 Giving Report: Donors Give Over $373,000 to Psychedelic Research and Education
Publication date: 07-27-2022
Open full article in lightbox
In June 2022, over 1,000 donors gave $373,433 in donations and pledges. We are so grateful to these supporters who advance our shared vision of creating safe and legal opportunities for the beneficial uses of psychedelics.Donors supported the following initiatives in June: general support ($335,135); Health Equity ($36,777); research-related projects ($1,308); harm reduction ($213).We extend a special thank you to our community of 815 monthly donors who contributed a total of $31,609 in June. Your support is vital in making our programs sustainable.We are honored to support a number of mission-aligned organizations by providing fiscal sponsorship so that contributions for their social benefit projects may be tax-deductible as allowed by law. An additional $480,750 was donated to organizations that MAPS fiscally sponsors including: Empyrean Temple ($267,391); Indigenous Medicine Conservation Fund ($125,000); Alma Institute ($54,045); ICEERS ($30,125); Brooklyn Psychedelic Society ($3,000); North Star Project ($1,000); Pearl Psychedelic Institute ($129); Aniwa ($25); MAPS Canada ($20); People of Color Psychedelic Collective ($10); and Bluelight ($5).
Tribute
We recognize that, for many of our supporters, the inspiration to support psychedelic science and education is close to their hearts. We are grateful to honor these special connections. June honorees include:Charles Phillips
Gratitude
We appreciate donations of any size and are particularly grateful to the following supporters for their generous contributions of $1,000 or more:
Unrestricted
The Rose Fund ($200,000)Leafy Tunnel Ltd. ($49,975)Catherine Oxenberg ($10,000)Trippin Ape Tribe ($9,678)Mason Vranes ($6,000)Buckmaster Foundation ($3,000)Rollkit.net in partnership with Rollsafe.org ($2,512)Carter Thomas ($2,500)Garrett Greenburg ($2,500)Anonymous ($2,000)Anonymous ($1,100)Eli Dickinson and Kat Zambon ($1,000)Jack Wolcowitz ($1,000)Jerry Greenfield ($1,000)Jiri Techet ($1,000)Mike Roberts ($1,000)Tom Link and Kristi Kremers ($1,000)
Health Equity
Joe and Sandy Samberg Foundation ($25,000)Anonymous ($11,362)
Honorarium
Sun Valley Wellness Institute ($8,000)American Society of Clinical Psychopharmacology ($2,500)
Fiscal Sponsorships
William H. Donner Foundation – Indigenous Medicine Conservation Fund ($125,000)Anonymous – Empyrean Temple ($80,000)Jeffrey and Beatrice Altman – Empyrean Temple ($50,000)Michael and Lisa Cotton – Alma Institute ($50,000)Spencer Kimball Family Foundation – Empyrean Temple ($50,000)Dr. Bronner’s Magic Soaps – ICEERS ($30,000)Merrifield Family Charitable Fund – Empyrean Temple ($30,000)Salman Behbehani – Empyrean Temple ($25,000)Peter Mattis Family Foundation – Empyrean Temple ($20,000)Heidi Berg – Alma Institute ($3,800)Mary Ellen and Darryl Pugh – Brooklyn Psychedelic Society ($3,000)Hilary Karls – Empyrean Temple ($1,000)Juan Pablo Cappello – North Star Project ($1,000Psychedelic research is again being conducted under federal guidelines, but significant government funding for such studies is just now becoming available with major foundations (not run by the founders) still not yet supporting this research. Together, we can legalize psychedelic medicine. Donate now at . The post
June 2022 Giving Report: Donors Give Over $373,000 to Psychedelic Research and Education
appeared first on
Multidisciplinary Association for Psychedelic Studies - MAPS
.
MDMA Therapy Training Program Update: July 2022
MDMA Therapy Training Program Update: July 2022
Publication date: 07-27-2022
Open full article in lightbox
In June 2022, the MDMA Therapy Training Team delivered two more trainings, including a week-long in-person training retreat in New York and a week-long training in California in collaboration with the California Institute of Integral Studies (CIIS). The New York training was led by mentor trainers Bruce Poulter, MPH, and Marcela Ot’alora G., MA, LPC. In addition to the synchronous and online course content, the training retreat incorporated art therapy projects, an evening music experiential evening, and Holotropic Breathwork, among other immersive learning components. The retreat was supported by a team of Assistant Trainers including Harvey Schwartz, Ph.D., LCP; Veronika Gold, LMFT; Jennifer Jones, LCSW; Genesee Herzberg, LCP; and Jason Butler, Ph.D., LCP. The CIIS training was led by mentor trainers Michael Mithoefer, M.D., and Annie Mithoefer, BSN, and supported by Assistant Trainers Eric Sienknecht, Ph.D., LCP, and Joanna Simundic, LPC, LCSW. The next training will be a week-long collaboration with Naropa University for their inaugural certificate cohort, running July 31 – August 7.
Upcoming 2022 Trainings
The has been posted on the training website, including options for a blended (online/in person) training format. Blended Format Cohorts:
September 12-18, North Carolina
• Online Course starts in August
September 25 – October 1, Colorado
• Online Course starts in August
October 9-14, New York
• Online Course starts in September
Application Information
We are now accepting applications for the above training programs. () Previously submitted applications will remain on file and will be reviewed for upcoming training opportunities. Guided by our commitment to deliver on our public benefit promise that
everyone deserves an equal opportunity to heal
, MAPS Public Benefit Corporation (MAPS PBC) is growing its MAPS Health Equity Leadership Program for Providers (formerly Health Equity Scholarship)
.
Establishing a trusting relationship between providers and patients is essential to effective therapy, and longstanding evidence has shown that the alignment of the social identities between giver and receiver of therapy improves treatment outcomes, safety, and trust. For eligible applicants interested in applying for our Health Equity Leadership Program, .The post
MDMA Therapy Training Program Update: July 2022
appeared first on
Multidisciplinary Association for Psychedelic Studies - MAPS
.
Statement: Biden Administration Preparing for Potential FDA Approval of MDMA-Assisted Therapy for PTSD
Statement: Biden Administration Preparing for Potential FDA Approval of MDMA-Assisted Therapy for PTSD
Publication date: 07-27-2022
Open full article in lightbox
Yesterday, a from the U.S. Department of Health and Human Services was describing the Food and Drug Administration’s “anticipated approval…within approximately 24 months” of psychedelic-assisted therapies. The letter indicated that the Substance Abuse and Mental Health Services Administration is exploring establishment of a Federal Task Force to address the complex issues associated with the commercialization of psychedelic medicines, including clinical, regulatory, and public policy matters. We applaud the Biden Administration for taking psychedelic-assisted therapies, and their potential to treat life-threatening mental health conditions, seriously. A Federal Task Force on psychedelic-assisted therapies should take a multidisciplinary approach to ensuring that red tape, administrative delays, or insurance coverage questions don’t leave Americans suffering as they seek to access approved treatments.For the first time, research that has been driven by philanthropists could additionally be supported by the same types of Federal grants that have funded other health care revolutions and develop patient access strategies that prioritize public benefit over profit. For decades, we have been making the case for what the Administration is now acknowledging: psychedelic-assisted therapies may become a key in addressing the most urgent mental health challenges of our time and reducing needless suffering.
, Founder and Executive Director, MAPS
NOTE
The safety and efficacy of MDMA-assisted therapy is currently under investigation. It has not yet been approved by the FDA or other regulatory authorities, does not work for everyone, and carries risks even in therapeutic settings. These statements are no guarantee of future regulatory approval or availability of MDMA-assisted therapy. These statements necessarily involve known and unknown risks and uncertainties, which may cause actual outcomes to differ materially from our projections.###
ABOUT
Founded in 1986, MAPS is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS is sponsoring the most advanced psychedelic therapy research in the world: Phase 3 clinical trials of MDMA-assisted therapy for PTSD. Since MAPS was founded, philanthropic donors and grantors have given more than $130 million for psychedelic and marijuana research and education. MAPS has earned both the and a .The post
Statement: Biden Administration Preparing for Potential FDA Approval of MDMA-Assisted Therapy for PTSD
appeared first on
Multidisciplinary Association for Psychedelic Studies - MAPS
.
MDMA and Healing a Dis-regulated Nervous System
MDMA and Healing a Dis-regulated Nervous System
Publication date: 07-21-2022
Open full article in lightbox
“I have worked with a lot of medicine on my healing journey. Dozens of ayahuasca ceremonies. Extensive experience with psilocybin, ketamine, kambo, and deep sessions with 5-MeO. While I’ve had some success in healing my traumas and emotional wounds, something still held on. Something I couldn’t let go of no matter how hard I tried. The root of my daily suffering seems to be based in a dis-regulated nervous system. The fear and discomfort I carry feels like it was acquired at a young age, likely pre-verbal. An existential pain, of not being ok, of not being safe or good. Of being unworthy, and a burden. It manifests as a slight tension and holding in my body, a slight sense of vigilance and elevation, all of the time. I am totally functional in life, but it’s really hard for me to deeply relax, to feel joy and ease, and to feel completely safe in social situations. And I know I can’t handle living like this any longer. I sat with Xxx and Xxxxx for their therapy protocol. Our overall session lasted almost 7 hours. We dosed 130mg of MDMA, and proceeded into talk therapy. I talked about my life story, my traumas, my fears and desires. 90 minutes in, we added an MDMA booster along with 1.5g of mushrooms. The discussion went deeper, and I felt safe opening up and sharing vulnerably. We then began the 5-MeO protocol, starting with the lowest dose vaporizer pen, and steadily working our way up. Bit by bit, my heart opened to the medicine, as we continued on the protocol. Normally I have a strong somatic reaction to 5, tensing and shaking my body, and feeling some visceral discomfort. This time, I was completely willing to welcome it into my system. I’ve never felt so open to the medicine, even at the maximum doses, feeling it penetrate directly into my heart space and the pain that I held there. I began having powerful emotional purges, crying the tears that I’d been holding on to my entire life. I felt the emotion deeply, accepted it fully, with compassion, and somehow knew that it was safe to let it go. I literally felt the energy move out of my system, being replaced with a powerful love for myself. “By my very existence on this earth I am worthy of love!”, I exclaimed. “I love myself so fucking much!” It was the most penetrating experience I’ve ever had with 5, where I didn’t resist it, and didn’t have these massive somatic releases. The MDMA kept my heart open and I fully accepted it as it went deep into my core. It was by far the most profound and effective medicine experience I’d ever had. As I write this, 2 weeks after our session, I sit here with the most regulated and free-flowing nervous system I’ve had in my life. There is a vastness in my heart that I hadn’t previously had access to, and I’ve been practicing affirmations to reprogram and fill that space with immense self-love. I am by no means “happy” at all times – there is still a fair amount of emotion moving through me. But, for once, it is moving, and I feel joy as I welcome it to move through me and out of me, without the tension, blockages, and negative self talk. I feel safe and open to feel and express it. In the space in between, I feel safe, curious, and excited to connect with other humans and this marvelous world. In all of the work I’ve done on my healing journey, this is what I’d been looking for. This is it. I am extremely grateful to Xxx and Xxxxx, both for this protocol and for their level of care and integrity in their work. It’s easy to feel the immense love they radiate as they share these gifts with the world.”The post
MDMA and Healing a Dis-regulated Nervous System
appeared first on
Multidisciplinary Association for Psychedelic Studies - MAPS
.
First Participant Completes Treatment in Phase 2 Study at the Bronx, New York Veterans Affairs Medical Center
First Participant Completes Treatment in Phase 2 Study at the Bronx, New York Veterans Affairs Medical Center
Publication date: 07-19-2022
Open full article in lightbox
Enrollment is continuing for our Phase 2, open-label study on the effectiveness of MDMA-assisted therapy in U.S. Veterans with chronic PTSD. This study is a comparative study that assesses two versus three active MDMA-assisted sessions.As of July 19, 2022, one subject completed the trial. Two additional subjects have been treated, and four subjects are enrolled into this study.The post
First Participant Completes Treatment in Phase 2 Study at the Bronx, New York Veterans Affairs Medical Center
appeared first on
Multidisciplinary Association for Psychedelic Studies - MAPS
.
First Participant Screened in Open-Label, Phase 2, Multicenter Feasibility Study of Manualized MDMA-Assisted Therapy with an Optional fMRI Sub-Study Assessing Changes in Brain Activity in Subjects with PTSD in Europe
First Participant Screened in Open-Label, Phase 2, Multicenter Feasibility Study of Manualized MDMA-Assisted Therapy with an Optional fMRI Sub-Study Assessing Changes in Brain Activity in Subjects with PTSD in Europe
Publication date: 07-18-2022
Open full article in lightbox
On July 18, 2022, the first UK participant in our open-label Phase 2 study of MDMA-assisted therapy for PTSD was screened by the research team at the Institute of Psychiatry, Psychology & Neuroscience at King’s College London – South London and Maudsley NHS Trust (KCL-SLaM). The site principal investigator is Dr. James Rucker.The post
First Participant Screened in Open-Label, Phase 2, Multicenter Feasibility Study of Manualized MDMA-Assisted Therapy with an Optional fMRI Sub-Study Assessing Changes in Brain Activity in Subjects with PTSD in Europe
appeared first on
Multidisciplinary Association for Psychedelic Studies - MAPS
.
MAPS Launches Psychedelic Fundamentals, an Online Education Curriculum From Leading Psychedelic Organization
MAPS Launches Psychedelic Fundamentals, an Online Education Curriculum From Leading Psychedelic Organization
Publication date: 07-14-2022
Open full article in lightbox
Psychedelic Fundamentals
is the initial offering in the new MAPS Digital Learning program introducing learners to the most important aspects of psychedelic history, research, uses, and harm reduction
The series of short, easy-to-follow modules is the perfect starting point for people trying to learn about psychedelics for the first time, but is also useful for psychedelic veterans looking to refine their knowledge
“
This is the drug training we should have all received as teenagers.”
The world’s leading authority on psychedelics, the (MAPS), announced the launch of
Psychedelic Fundamentals,
an online psychedelic education program which provides people with accurate, evidence-based information about psychedelics. The educational curriculum, developed in collaboration with and delivered over five modules, covers a range of topics including psychedelic history, science, clinical research, therapeutic uses, and harm reduction. “
Psychedelic Fundamentals
is a program for everyone – even for people who may never take a psychedelic themselves. Within the next few years, millions of people may be eligible for a prescription of psychedelic-assisted therapy. Having access to a science-based educational curriculum, backed by MAPS’ nearly four decades as the world leader in psychedelics, will give people shared language and knowledge to better care for loved ones who may be looking into these treatments.”
, Director of Digital, MAPS
Psychedelic Fundamentals
serves as a perfect launching point for those completely new to psychedelics and seeking the basic knowledge of how psychedelics work, their effects, and their history. This course is valuable to people who are curious about the use of psychedelics for therapeutic purposes for themselves or a loved one, and for people looking for up-to-date information about cutting-edge psychedelic research. Experienced psychedelic users will find this guide a useful resource with the latest on psychedelic policy, as well as harm reduction strategies to increase the likelihood of an “ideal” experience.Since 1986, MAPS has endeavored to counteract the broad public misinformation disseminated over the decades of the War on Drugs. The gain in public interest in psychedelics has left many with a desire to learn more about the transformative potential of these substances, but there are limited resources for people looking for an authoritative curriculum. “This is the drug training we should have all received as teenagers. It was not just about the different substances, but the benefits they can have, as well as how to integrate those experiences, and also some useful tips for how to be there for those in need while they are having them. So much valuable information in one place, with the awareness to tell users to be cautious and aware of what they are doing.”
Proficient
Psychedelic Fundamentals
learner
The
Psychedelic Fundamentals
coursework is divided into modules including: Psychedelics & Non-Ordinary States of Consciousness, The Current State of Psychedelics, Psychedelic Brain Science 101, Comparing Psychedelic Substances, and Psychedelic Trip Planning & Harm Reduction. Each module contains a series of short, easy-to-follow lessons complimented by MAPS’ new online community platform, where fellow learners and psychedelic advocates can connect.The
Psychedelic Fundamentals
digital learning course is available for purchase on the.
Psychedelic Fundamentals Course
$
29.99
###
ABOUT
Founded in 1986, MAPS is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS is sponsoring the most advanced psychedelic therapy research in the world: Phase 3 clinical trials of MDMA-assisted therapy for PTSD. Since MAPS was founded, philanthropic donors and grantors have given more than $130 million for psychedelic and marijuana research and education. MAPS has earned both the and a .The post
MAPS Launches Psychedelic Fundamentals, an Online Education Curriculum From Leading Psychedelic Organization
appeared first on
Multidisciplinary Association for Psychedelic Studies - MAPS
.
GH Research Reports First Quarter 2022 Financial Results and Provides Business Updates
GH Research Reports First Quarter 2022 Financial Results and Provides Business Updates
Publication date: 05-18-2022
Open full article in lightbox
GH Research Reports Full Year 2021 Financial Results and Provides Business Updates
GH Research Reports Full Year 2021 Financial Results and Provides Business Updates
Publication date: 03-28-2022
Open full article in lightbox
GH Research Reports Third Quarter 2021 Financial Results and Provides Business Updates
GH Research Reports Third Quarter 2021 Financial Results and Provides Business Updates
Publication date: 12-06-2021
Open full article in lightbox
GH Research Announces Successful Outcome of the Phase 2 part of its Phase 1/2 Clinical Trial of GH001 in Treatment-Resistant Depression
GH Research Announces Successful Outcome of the Phase 2 part of its Phase 1/2 Clinical Trial of GH001 in Treatment-Resistant Depression
Publication date: 12-06-2021
Open full article in lightbox
GH Research PLC Provides Business Updates and Reports Second Quarter 2021 Financial Results
GH Research PLC Provides Business Updates and Reports Second Quarter 2021 Financial Results
Publication date: 09-23-2021
Open full article in lightbox
GH Research PLC Announces Pricing of Initial Public Offering
GH Research PLC Announces Pricing of Initial Public Offering
Publication date: 06-25-2021
Open full article in lightbox
GH Research Announces Closing of $125 Million Oversubscribed Series B Financing
GH Research Announces Closing of $125 Million Oversubscribed Series B Financing
Publication date: 04-12-2021
Open full article in lightbox
GH Research Ltd. Announces Completion of Phase 1 Clinical Study with GH001 (5-Methoxy-N,N-Dimethyltryptamine) in Healthy Volunteers and Updates on Further Progress
GH Research Ltd. Announces Completion of Phase 1 Clinical Study with GH001 (5-Methoxy-N,N-Dimethyltryptamine) in Healthy Volunteers and Updates on Further Progress
Publication date: 11-19-2020
Open full article in lightbox
Latest Publications
–
Scientific literature 2020/2021
pulls refs test
References 2021
Importing BibTeX data...
0%
Contact
–
Get in touch…
pulls refs test
Get in touch...
Contact Dr. Christopher B. Germann
transmissions@psychedelic-lab.com
Your name
Your email
Subject
Your message
Please prove you are human by selecting the
Truck
.
Δ
Open form in lightbox window
Search
–
Intelligent search function
Intelligent Boolenan Search function (auto-completion)
Generic selectors
Exact matches only
Exact matches only
Search in title
Search in title
Search in content
Search in content
Search in excerpt
Search in posts
Search in posts
Search in pages
Search in pages
Search in posts
Search in posts
Search in pages
Search in pages
Search in posts
Search in posts
Search in pages
Search in pages
trials 2021
Top